The New Alzheimer’s Blood Test Can Find Pathology Twenty Years Early. It Cannot Tell You What Caused It.

What the test measures, what the new drugs reach, and what is correctable in the twenty years before either one has anything to say.

Dr. Justin Dearing, DC, DACNB, FIAMA, FAARM

The news is real

You may have seen the story. There is now a blood test that can detect the pathology behind Alzheimer’s disease, and in research settings it can find that pathology years before a person shows any symptom at all. There are also new drugs that clear that pathology out of the brain.

Both of these are real advances. Twenty years ago we could not see this process at all without a spinal tap or a specialized brain scan. Now it can be seen in a tube of blood.

I want to explain why this is a smaller step forward than the coverage suggests. The short version is that the test arrived before the answer did. The longer version is that the reason it is smaller is also the reason there is something you can do about it right now.

Why clearing amyloid is a smaller win than it sounds

Amyloid is a protein that builds up in the brain. Its accumulation is the defining feature of Alzheimer’s pathology, and it has been the primary target of drug development for about thirty years.

The new drugs do what they were designed to do. They clear plaque, in many patients down to very low levels.

Here is the finding that should reframe how you read the headlines. Decline continues anyway. It is slowed by a modest margin over roughly eighteen months. It is not stopped, and it is not reversed.

Sit with what that means. If amyloid were the cause of the disease, taking it out would end the disease. Taking it out does not end the disease. It slows it somewhat, in people who already have symptoms.

The most reasonable reading of that result is that amyloid is a link in the chain rather than the start of it. Something upstream drove the brain into producing and depositing it, and that something is still running after the plaque is gone.

I am not telling you these drugs are worthless. For a person with symptoms and confirmed pathology, a modest slowing is worth having, and the science behind them is impressive. What I am telling you is that the target sits far downstream of where the trouble begins, which is why the benefit is measured in months rather than years.

There is a second thing worth knowing about the test itself. A positive result means amyloid pathology is present. It does not mean a person has dementia or that they will develop it. A meaningful share of cognitively healthy adults over seventy-five are amyloid positive, and many of them never convert. The approved use of the test is for people who already have symptoms and are being evaluated for the cause. The pre-symptomatic detection described in the news comes from research studies, not from routine practice.

So a person can now receive a number that describes their risk, with no plan attached to it. That gap is what the rest of this article is about.

What was happening for twenty years before the test turned positive

Amyloid begins accumulating roughly fifteen to twenty years before the first symptom appears. That window is the entire story.

So ask the obvious question. What is happening during those twenty years?

A great deal, and almost none of it gets measured.

Metabolism becomes disordered. Blood sugar swings wider and sits higher. The immune system takes on a low level of activation that never fully resolves. The gut barrier and the bacterial community behind it drift, and inflammatory signaling starts moving upward from the gut toward the brain. Oxygen delivery and oxygen use decline. Breathing mechanics degrade quietly, decade over decade, until the diaphragm barely moves. Movement quality and coordination fall off. Old injuries and old concussions leave connections that never fully came back online. Brain networks lose stability. Social life contracts, and the daily demands that once kept a brain sharp fall away.

None of that is an event. There is no day it happens. It is an accumulation, and accumulation is invisible while it is happening.

By the time a blood test turns positive, your physiology has been changing for twenty years. The test finds the smoke. The fire has been burning since your fifties.

That is why I am not satisfied with a strategy that begins at the end. If the process runs for two decades before it announces itself, then those two decades are where the work belongs.

The prevention research found the right direction

Researchers already know this, and the studies exist.

The FINGER trial in Finland took more than a thousand older adults at elevated risk and ran four things at once for two years. Nutrition. Exercise, both strength and aerobic. Cognitive training. And monitoring of blood pressure, weight, and metabolic markers with follow-up when something was off. The group receiving all four held cognitive ground significantly better than the comparison group. The gains showed up most in executive function and processing speed, which are the abilities that govern planning, focus, and mental quickness.

US POINTER, the American version, tested roughly two thousand adults and did something clever. Its comparison group was not left alone. They received a self-guided version of the same program. Both groups improved. The structured group improved more. That both groups improved is the most encouraging finding in the trial, and it rarely gets mentioned.

So the direction is proven. Doing several things at once, on purpose, changes the trajectory. That deserves to be said plainly.

Here is what those studies could not do.

Exercise was prescribed by session count and by general intensity guidance. Nobody verified that the intensity actually matched each person’s metabolism. Nobody measured oxygen utilization. Nobody measured autonomic regulation, meaning the balance between the body’s stress and recovery systems. Nobody measured gut function or immune load. Nobody measured brain network activity.

And everyone received the same package regardless of what was actually limiting them. If the person whose problem is inflammatory load and the person whose problem is oxygen delivery both get the identical plan, the average result is hiding two different stories.

Four domains changed the trajectory while measuring almost nothing underneath them. That is not a criticism of the research. It is an argument for going further.

What we measure, and what each measurement answers

Where the immune system learns

Most people think of the gut as a digestion organ. That is the smaller half of the job.

The gut is also where your immune system is trained. Roughly two thirds of your immune tissue sits in the lining of your intestines, and that is where immune cells learn the difference between friend and enemy. They learn what to ignore, such as food and your own tissue, and what to attack. That training is called tolerance. It is not permanent. It has to be maintained daily, and the bacteria living in your gut are what maintain it, largely through compounds they produce from the fiber you eat.

This matters for the brain more than almost anywhere else in the body. Brain tissue is protected, and the immune system rarely encounters it under normal conditions. So when tolerance training degrades, the brain is one of the first places the immune system starts making mistakes.

How a small immune mistake becomes a large one

When the immune system first reacts to something it should have ignored, it usually reacts to one small piece of one protein. If the situation resolves, it stops there. If it does not resolve, and the tissue keeps getting stressed and releasing material, the immune system begins recognizing more pieces. First more pieces of the same protein. Then pieces of neighboring proteins in the same tissue.

Immunologists call this epitope spreading. In plain language, the response gets wider over time. It starts as one small argument and grows into a broad one.

This is why we run a neural antibody panel, and it is why the number of markers matters as much as which ones appear. One or two positives describe a narrow process. Positives across many different neural tissue types describe something that has been running longer and reaching further.

The breadth of the response tells us about duration and depth. It is not a measure of how sick someone is today.

Two more things the panel tells us. IgM antibodies point to an actively running arm of the response. IgG antibodies point to an established one with history behind it. When both appear together, we are usually looking at a process that started some time ago and has not shut off.

To be clear about what this is and is not: antibody panels do not diagnose disease. They show where the immune system has already made contact with neural tissue. That is a vulnerability map, and it tells us which areas are under load and where to concentrate the work.

Reading three tests together

Microbiome analysis, organic acids testing, and the neural antibody panel answer three different questions that only make sense next to each other.

Microbiome analysis answers whether the bacterial community that trains tolerance is intact, and whether the gut lining is holding. This is the upstream question.

Organic acids testing answers how the cells are performing. It shows mitochondrial output, which is cellular energy production. It shows oxidative burden, which is the wear of running under stress. It shows whether the raw materials for neurotransmitters are present and whether the B vitamin cofactors that drive those reactions are adequate. It also shows bacterial fermentation byproducts, which gives a second and independent view of the gut.

The neural antibody panel answers whether the immune system has already engaged neural tissue, and how far that engagement has spread.

Read together they describe a sequence. Tolerance training degrades. Inflammatory signaling rises. Cells running under inflammatory load produce energy less efficiently. Tissue under metabolic stress releases material the immune system was never meant to see. The response widens. Any one test is a snapshot. Together they show the order of events, and the order is what tells us where to start.

Measuring the brain itself

qEEG brain mapping measures the brain’s electrical rhythms and how well its networks communicate. It gives us numbers where most brain assessment gives impressions. Cognitive testing asks how a person performs on a task. qEEG asks how the underlying system is operating, and it tends to show change earlier than task performance does.

It also gives us a before and after. Different training targets different things. Infra-slow neurofeedback works on the slowest underlying rhythms, the ones that set the brain’s baseline stability. Z-score training targets connectivity and network stability, meaning how reliably regions coordinate with one another. When patients repeat a map after a course of training, we can see whether the pattern actually moved.

We are not treating a disease with this. We are retraining rhythm and coordination in a system that has lost some of both, and then measuring whether it worked.

Measuring metabolism while it is running

PNOĒ metabolic breath analysis measures your metabolism in action. Most metabolic testing samples blood at rest. This measures the air moving in and out of you during work, which tells us how efficiently your cells are actually converting oxygen into energy.

It also produces your VO2 max, the ceiling on how much oxygen your body can deliver and use. VO2 max is one of the strongest predictors of long term health we have, and it begins declining decades before anyone notices a problem. It is a number that goes quiet long before it goes loud.

Just as important, it tells us where your true training threshold sits. Nearly all exercise advice, including the exercise prescribed in the prevention trials, comes from a formula applied to your age or a percentage of an estimated maximum. Those formulas are wrong for a lot of people. Measured directly, we can prescribe the intensity that produces benefit for you rather than the intensity that produces it on average.

Retraining the connection

Functional neurological performance training is where measurement becomes work.

The connection between brain and body degrades over a lifetime. Old injuries do it. Concussions do it, including ones from decades ago that seemed minor at the time. Years of inflammatory signaling do it. Long stretches of sitting still do it. The result is that the brain gradually loses clean information from parts of the body and clean control over them, and it begins working around the gaps instead of through them.

Functional neurology retrains those connections directly. Eye movement, balance, coordination, and movement quality are the entry points, because those systems give the brain the fastest and richest feedback available. When the pathways sharpen, the brain receives better information and produces better control. People notice it in ordinary things. Steadier on their feet. Clearer under pressure. Less effort required to do what used to be automatic.

You cannot correct what you have never measured. That is the whole argument, and it is why we start with data instead of a protocol.

The daughters

The people who understand this fastest are usually women in their fifties and sixties who have already lived through it from the other side.

They spent years managing a parent’s decline. They know the arithmetic in a way nobody else does. Memory care runs into thousands of dollars a month and is rarely covered the way families expect. There are the unpaid hours. The reduced work. The career interrupted at exactly the wrong decade. There are the siblings who could not help, the marriage that took the strain, and a grief that started years before the funeral.

They watched a process they could not change, because by the time they were involved it was already late.

They come in and ask to be measured. Not because they are frightened, although some are. They come because they have decided to spend the money and the effort now rather than leave that bill to their own children.

That is not fear. That is one of the most clear-eyed decisions a person can make about their own aging. They saw a passive process play out in full, and they decided not to repeat it.

I cannot promise them an outcome and I do not try to. What I can do is show them where their physiology sits today, which parts of it are correctable, and whether the work is moving the numbers. That is a different conversation than the one they had in their parent’s neurologist’s office, and they recognize the difference immediately.

The men

The other group I did not expect is men over seventy who arrive on their own initiative.

They are not in crisis. They have usually decided they are not finished yet, and they want to know what is still available to them. They have been among the most rewarding patients I have worked with, and the results have been better than I anticipated.

What they report is not a test score. They say they feel brighter. More present. Several have described it as something lifting that had been sitting on them for years, a weight they had stopped noticing because it had been there so long.

Their measurements move as well. But the thing they tell their wives about is that they feel like themselves again.

There is no cure. There is a window.

There is no cure for Alzheimer’s disease. Nobody has one, I do not have one, and you should be careful with anyone who suggests otherwise.

What exists is a window. It runs about twenty years, it opens long before anything shows up on a test, and almost all of it is currently spent unmeasured.

Inside that window are things that are correctable. How efficiently your cells use oxygen. Whether your gut is generating inflammatory signal. Where your immune system has already engaged neural tissue. How stable your brain networks are. How well your brain and body are still talking to each other. None of these appear on a blood test result. All of them can be measured, and all of them respond to work.

A blood test can now tell you that something has already accumulated. It cannot tell you what drove it, and it cannot tell you what to do next.

That part is still yours, and you can start before the test has anything to say.

Where this begins

The New Patient Consultation is the starting point. We measure first, then build the plan from what we find, and we retest so you can see whether it is working.

‍

‍